Revenue

With promising clinical data and a streamlined FDA path, a smarter molecule could finally offer a better, more tolerable treatment for idiopathic pulmonary fibrosis.

Bowman Consulting's acquisition of RPT Alliance is a strategic move to solve the energy crisis facing AI and data centers with rapid-deployment power.

Sensorion clears a key safety hurdle for its infant hearing loss gene therapy, but early data reveals a tight race to market against formidable rivals.

OSE Immunotherapeutics is taking back a key drug from AbbVie, betting its own cash on a bigger prize. What does this strategic pivot reveal about pharma R&D?

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

Fresh off its spin-off, the US metals processor is in talks to acquire a German giant, a move that could reshape the global steel industry.

New 52-week data shows Protagonist and Takeda's drug slashes phlebotomy needs, signaling a major shift in quality of life for polycythemia vera patients.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.

Emera renewed its C$600M equity program. We dive into the $20B plan driving this move and what it means for the future of energy grids and investors.

AMC sells its Hycroft Mining stake to gold titan Eric Sprott for $24.1M, ending a curious diversification to double down on its core cinema business.

Alerus Financial’s 5% dividend increase isn’t just a payout; it’s a story of strategic diversification and resilience in a volatile banking sector.

A junior miner's auditor and finance chief changes signal a calculated move to de-risk its path to becoming a major developer of a 'green' gold mine.

With shareholder approval secured, the HNI-Steelcase merger is set to create a $5.8B powerhouse. But can it deliver on its $120M synergy promise?

A 209kg opium seizure reveals how Canada's billion-dollar investment in AI and intelligence is disrupting sophisticated global drug smuggling networks.

As Virginia faces slowing growth, the business community presents a new decade-long economic plan to Governor-elect Spanberger. Can it deliver prosperity?

Ottawa's new protectionist policies for steel and lumber are more than a trade strategy; they're a massive public health intervention for at-risk communities.

Swedish innovator SciBase is overhauling its capital structure with a complex warrant buyback. Is this a strategic masterstroke or a necessary defensive play?

A Canadian firm's breakthrough promises to produce renewable natural gas at price parity with fossil fuels. Is this the key to unlocking a greener economy?

USA Pickleball's exclusive DUPR deal aims to unify the sport, but a single rating system brings both professional legitimacy and player controversy.

Following a strategic merger, the National Down Syndrome Society appoints six new leaders, signaling a new era of inclusive, research-driven advocacy.